Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment - Uchino, Junji; Nakao, Akira; Tamiya, Nobuyo; Kaneko, Yoshiko; Yamada, Tadaaki; Yoshimura, Kenichi; Fujita, Masaki; Takayama, Koichi (Medicine (Baltimore), 2018)
Keywords: Acrylamides; Aged; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm - genetics; ErbB Receptors - drug effects; ErbB Receptors - genetics; Female; Genes, erbB-1 - genetics; Humans; Lung Neoplasms - pathology; Male; Mutation - drug effects; Mutation - genetics; Neoplasm Staging; Piperazines - administration & dosage; Piperazines - pharmacology; Prospective Studies; Protein Kinase Inhibitors - pharmacology; Study Protocol Clinical Trial